Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1843798 | 1.00 | PDE4A (0.43) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL28292381 | 1.00 | PDE4A (0.43) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL18825591 | 1.00 | PDE4A (0.43) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL27438858 | 0.94 | PDE4A (0.52) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL1704734 | 0.94 | PDE4A (0.52) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL1062215 | 0.94 | PDE4A (0.52) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL8658675 | 0.92 | PDE4A (0.50) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| Bicarbonate SCHEMBL30050792 | 0.90 | PDE4A (0.53) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| Acrylamide SCHEMBL6682076 | 0.86 | PDE4A (0.44) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| Fructose SCHEMBL9263130 | 0.79 | CYP2C9 (0.48) | PDE4ALMNAL3MBTL1TDP1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220195424-A1 | Chemical Capping for Template Switching | NEW ENGLAND BIOLABS, INC. (US) | 2022-06-23 | — | — | US | claimed |
| US-9994856-B2 | Method for increasing the activity of a cystic fibrosis transmembrane conductance regulator protein | PROQR THERAPEUTICS II B.V. (NL) | 2018-06-12 | — | — | US | claimed |
| US-20170152518-A1 | OLIGONUCLEOTIDES FOR MAKING A CHANGE IN THE SEQUENCE OF A TARGET RNA MOLECULE PRESENT IN A LIVING CELL | PROQR THERAPEUTICS B.V. (NL) | 2017-06-01 | — | — | US | claimed |
| US-9605255-B2 | Oligonucleotides for making a change in the sequence of a target RNA molecule present in a living cell | PROQR THERAPEUTICS II B.V. (NL) | 2017-03-28 | — | — | US | claimed |
| EP-2852668-B1 | OLIGONUCLEOTIDES FOR MAKING A CHANGE IN THE SEQUENCE OF A TARGET RNA MOLECULE PRESENT IN A LIVING CELL | PROQR THERAPEUTICS II BV (NL) | 2016-04-27 | — | — | EP | claimed |
| US-20150197744-A1 | OLIGONUCLEOTIDES FOR MAKING A CHANGE IN THE SEQUENCE OF A TARGET RNA MOLECULE PRESENT IN A LIVING CELL | PROQR THERAPEUTICS II B.V. (NL) | 2015-07-16 | — | — | US | claimed |
| EP-2852668-A1 | OLIGONUCLEOTIDES FOR MAKING A CHANGE IN THE SEQUENCE OF A TARGET RNA MOLECULE PRESENT IN A LIVING CELL | ProQR Therapeutics B.V. (NL) | 2015-04-01 | — | — | EP | claimed |
| WO-2014011053-A1 | OLIGONUCLEOTIDES FOR MAKING A CHANGE IN THE SEQUENCE OF A TARGET RNA MOLECULE PRESENT IN A LIVING CELL | PROQR THERAPEUTICS B.V. (NL) | 2014-01-16 | — | — | WO | claimed |
| JP-4836327-B2 | — | — | 2011-12-14 | — | — | JP | claimed |
| CN-100389196-C | Cancer cell vaccine | ANTIGEN EXPRESS INC (US) | 2008-05-21 | — | — | CN | claimed |
| US-20030054365-A1 | MHC class II antigen presenting cells containing oligonucleotides which inhibit Ii protein expression | ANTIGEN EXPRESS, INC. | 2003-03-20 | — | — | US | claimed |
| JP-2002531582-A | — | — | 2002-09-24 | — | — | JP | claimed |
| US-6368855-B1 | A CELL CONTAINING A SPECIFIC REGULATOR OF AN INVARIANT CHAIN PROTEIN AND CAN HYBRIDIZE TO SPECIFIC TARGET RNA REGIONS UNDER PHYSIOLOGICAL CONDITIONS DUE TO A COPOLYMER | ANTIGEN EXPRESS, INC. | 2002-04-09 | — | — | US | claimed |
| CN-1332799-A | Cancer cell vaccine | ANTIGEN EXPRESS INC (US) | 2002-01-23 | — | — | CN | claimed |
| EP-1135482-A1 | CANCER CELL VACCINE | Antigen Express, Inc. (US) | 2001-09-26 | — | — | EP | claimed |
| CN-1060781-C | Phosphonootropic monoester nucleic acids, process for their preparation and their use | HOECHST AG (DE) | 2001-01-17 | — | — | CN | claimed |
| WO-2000034467-A1 | CANCER CELL VACCINE | ANTIGEN EXPRESS, INC. (US) | 2000-06-15 | — | — | WO | claimed |
| CN-1138588-A | Phosphonootropic monoester nucleic acids, process for their preparation and their use | HOECHST AG (DE) | 1996-12-25 | — | — | CN | claimed |
| US-5587469-A | USEFUL AS ?ANTISENSE AGENTS? THAT ARE CAPABLE OF SPECIFIC HYBRIDIZATION WITH A NUCLEOTIDE SEQUENCE OF AN RNA | ISIS PHARMACEUTICALS, INC. (US) | 1996-12-24 | — | — | US | claimed |
| US-4469863-A | ANTITUMOR AGENTS, VIRICIDES | GENTA INCORPORATED | 1984-09-04 | — | — | US | claimed |